Tenon Medical Faces Nasdaq Delisting Warning Over Bid Price
Ticker: TNONW · Form: 8-K · Filed: Jan 11, 2024 · CIK: 1560293
| Field | Detail |
|---|---|
| Company | Tenon Medical, Inc. (TNONW) |
| Form Type | 8-K |
| Filed Date | Jan 11, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | bearish |
Complexity: simple
Sentiment: bearish
Topics: delisting-notice, compliance-risk, stock-price, regulatory-filing
TL;DR
**TNON got a Nasdaq delisting warning for low stock price, big trouble if they can't fix it.**
AI Summary
Tenon Medical, Inc. (TNON) announced on January 4, 2024, that it received a notice from Nasdaq indicating it no longer meets the minimum bid price requirement for continued listing. This means TNON's stock price has fallen below $1.00 for 30 consecutive business days. This is a critical development for shareholders because if the company cannot regain compliance, its stock could be delisted from Nasdaq, potentially making it harder to trade and reducing its liquidity and investor appeal.
Why It Matters
This notice signals significant financial distress for Tenon Medical, as delisting could severely impact the stock's liquidity and investor confidence, making it a much riskier investment.
Risk Assessment
Risk Level: high — The risk is high because delisting from a major exchange like Nasdaq can severely limit a stock's tradability and investor interest.
Analyst Insight
A smart investor would carefully evaluate Tenon Medical's plan to regain Nasdaq compliance and consider the increased risk of delisting before making any investment decisions. Existing shareholders should monitor the situation closely.
Key Numbers
- $0.001 — Par Value per Share (The par value of Tenon Medical's Common Stock.)
Key Players & Entities
- Tenon Medical, Inc. (company) — the registrant receiving the delisting notice
- Nasdaq (company) — the exchange issuing the delisting notice
- $0.001 (dollar_amount) — par value per share of Common Stock
- January 4, 2024 (date) — date of earliest event reported (receipt of delisting notice)
Forward-Looking Statements
- Tenon Medical will need to execute a reverse stock split or significantly improve its financial performance to regain Nasdaq compliance. (Tenon Medical, Inc.) — high confidence, target: Within 180 days of January 4, 2024
FAQ
What is the primary reason Tenon Medical, Inc. received a notice from Nasdaq?
Tenon Medical, Inc. received a notice from Nasdaq because it failed to satisfy a continued listing rule or standard, specifically the minimum bid price requirement, as indicated in the 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing' item information.
When did Tenon Medical, Inc. report the earliest event related to this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 4, 2024, which is the date Tenon Medical, Inc. received the notice from Nasdaq.
What is the trading symbol for Tenon Medical, Inc. common stock?
The trading symbol for Tenon Medical, Inc. common stock is TNON, as specified in the filing under 'Securities registered pursuant to Section 12(b) of the Act'.
What is the par value of Tenon Medical, Inc.'s Common Stock?
The par value of Tenon Medical, Inc.'s Common Stock is $0.001 per share, as stated in the filing under 'Common Stock, par value $0.001 per share'.
What is Tenon Medical, Inc.'s business address?
Tenon Medical, Inc.'s business address is 104 Cooper Court, Los Gatos, CA 95032, with a business phone number of (408) 649-5760, according to the filing's company data.
Filing Stats: 642 words · 3 min read · ~2 pages · Grade level 13 · Accepted 2024-01-11 17:30:57
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share TNON The Nasdaq Stock Mar
Filing Documents
- ea191545-8k_tenon.htm (8-K) — 28KB
- 0001213900-24-003047.txt ( ) — 239KB
- tnon-20240104.xsd (EX-101.SCH) — 4KB
- tnon-20240104_def.xml (EX-101.DEF) — 26KB
- tnon-20240104_lab.xml (EX-101.LAB) — 36KB
- tnon-20240104_pre.xml (EX-101.PRE) — 25KB
- ea191545-8k_tenon_htm.xml (XML) — 5KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 4, 2024, Tenon Medical, Inc. (the "Company") received a written notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") dated January 4, 2024, indicating that, as a result of Frank Fischer's resignation from the Board of Directors of the Company ("Board"), audit committee of the Board (the "Audit Committee") and compensation committee of the Board (the "Compensation Committee"), effective November 30, 2023, that the Company is not currently in compliance with Nasdaq Listing Rule 5605, which requires that (i) a majority of the Board be comprised of independent directors, (ii) the Audit Committee is comprised of at least three independent directors and (iii) the Compensation Committee is comprised of at least two independent directors. The Company currently has six (6) directors, only three (3) of which qualify as independent directors. In addition, the Audit Committee currently is comprised of only two independent directors and the Compensation Committee is only comprised of one independent director. In accordance with Nasdaq Listing Rule 5605(b)(1)(A), the Company has a "cure period" of until the earlier of the Company's next annual shareholders' meeting or November 30, 2024, or if the next annual shareholders' meeting is held before May 28, 2024, then the Company must evidence compliance no later than May 28, 2024. The Company intends to elect one or more independent directors to serve as a member of the Board, the Audit Committee and the Compensation Committee during this cure period. The Notice has no immediate effect on the listing or trading of the Company's common stock on The Nasdaq Capital Market. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 11, 2024 TENON MEDICAL, INC. By: /s/ Steven M. Foster Name: Steven M. Foster Title: Chief Executive Officer and President 2